Brief: Interpace Biosciences Announces Results Of Seminal Clinical Validation Study For Thyroid Assays

Interpace Biosciences

26/10/2020 11:18

Oct 26 (Reuters) - Interpace Biosciences Inc  IDXG.O :
    * INTERPACE BIOSCIENCES ANNOUNCES RESULTS OF SEMINAL
CLINICAL
VALIDATION STUDY FOR THYROID ASSAYS
    * INTERPACE BIOSCIENCES INC - THYGENEXT + THYRAMIR
COMBINATION
TESTING YIELD HIGHEST POSITIVE PREDICTIVE VALUE AND SIMILAR
NEGATIVE PREDICTIVE VALUE
    * INTERPACE BIOSCIENCES INC - APPROXIMATELY 25% OF THYROID
NODULE
FINE NEEDLE ASPIRATES HAVE CYTOLOGY THAT IS INDETERMINATE FOR
MALIGNANT DISEASE

Source text for Eikon:  ID:nGNX7D4ZtC 
Further company coverage:  IDXG.O 

 ((Reuters.Briefs@thomsonreuters.com;))